Mar 27,2024
Mumbai, March 26, 2024. An exclusive distribution and marketing agreement was today announced between Sanofi India and Cipla for Sanofi’s Central Nervous System (CNS) product line in India. As part of this collaboration, Cipla will handle the distribution of Sanofi India’s six CNS brands, which include the industry-leading Frisium® brand of anti-epileptic drugs.
Cipla will make use of its skills and strong India-wide network of distributors, institutions, and market outreach programmes to expand access to these treatments for patients who need them, while Sanofi India will continue to own, import, and manufacture its entire range of CNS products across plants in India and abroad.
Rodolfo Hrosz, Managing Director, Sanofi India Limited, said “Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India.”
Mr. Achin Gupta, Chief Executive Officer – One India Business, Cipla Limited, said “Enhancing access to high quality treatments is central to our purpose of ‘Caring for Life’. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients.”
Sanofi India continues to focus on accelerating its strong innovation pipeline into India, across multiple therapeutic areas including Diabetes, Transplants, Rare Diseases, Consumer Healthcare and Vaccines.
Source: Pharma
To Sponser Contact Us